They found that lapatinib, but not other EGFR inhibitors synergized the anti-tumor activity of proteasome inhibitors both in vitro and in vivo, suggesting that treatment of TNBCs with lapatinib may enhance their oncogene addiction to NF-κB, and thus augment the anti-tumor activity of proteasome inhibitors. Here, EGFR is linked to neoplasm.